Wall Street Zen Downgrades Cytokinetics (NASDAQ:CYTK) to Sell

Key Points

• Wall Street Zen downgraded Cytokinetics to “sell” from “hold,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $100.85.
• Cytokinetics reported better-than-expected quarterly results, with revenue of $28.62 million and an adjusted loss of $1.50 per share, but revenue declined 57.1% year over year and losses remain substantial.
• Shares opened at $76.76 after falling 5.7%; meanwhile, executives sold more than $888,000 of stock in disclosed transactions, contributing to approximately $9.1 million in insider sales over the past 90 days.

Cytokinetics (NASDAQ:CYTK - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently weighed in on CYTK. Weiss Ratings reissued a "sell (d-)" rating on shares of Cytokinetics in a report on Friday, July 17th. Needham & Company LLC upped their target price on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday. Citizens Jmp boosted their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a "market outperform" rating in a report on Friday. HC Wainwright raised their price objective on Cytokinetics from $136.00 to $140.00 and gave the company a "buy" rating in a research note on Monday, May 11th. Finally, Mizuho lifted their price objective on Cytokinetics from $100.00 to $118.00 and gave the stock an "outperform" rating in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.85.

Cytokinetics Trading Down 5.7%

Shares of CYTK stock opened at $76.76 on Friday. Cytokinetics has a 12 month low of $32.89 and a 12 month high of $88.31. The stock has a market capitalization of $9.55 billion, a P/E ratio of -10.63 and a beta of 0.38. The firm's 50 day moving average is $78.91 and its 200 day moving average is $70.90.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to analysts' expectations of $17.59 million. Cytokinetics's revenue was down 57.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) EPS. On average, equities analysts predict that Cytokinetics will post -6.2 EPS for the current year.

Insider Buying and Selling at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 3,500 shares of the stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $80.59, for a total value of $282,065.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares in the company, valued at $12,402,962.18. This trade represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $80.87, for a total value of $606,525.00. Following the completion of the transaction, the chief executive officer directly owned 377,820 shares of the company's stock, valued at approximately $30,554,303.40. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 115,179 shares of company stock valued at $9,126,054 over the last 90 days. 2.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 673 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Cytokinetics during the 4th quarter worth $27,000. Kestra Advisory Services LLC bought a new stake in shares of Cytokinetics during the 4th quarter valued at $29,000. Quarry LP bought a new stake in shares of Cytokinetics during the 3rd quarter valued at $30,000. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Cytokinetics in the 4th quarter worth $32,000.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source